Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 8NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thromboembolism 1Pancreatic Neoplasms 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Dalteparin × Clear all
NCT00462852 2013-08-12

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡